JO3158B1 - عملية تحضير 4- {4 - [({[4-كلورو-3- (ترايفلوروميثيل) -فينيل] أمينو} الكربونيل)أمينو]-3-فلوروفينوكسي}- } -n-ميثلبريدين-2-كربوكساميد، وملح ومونوهيدرات منه - Google Patents

عملية تحضير 4- {4 - [({[4-كلورو-3- (ترايفلوروميثيل) -فينيل] أمينو} الكربونيل)أمينو]-3-فلوروفينوكسي}- } -n-ميثلبريدين-2-كربوكساميد، وملح ومونوهيدرات منه

Info

Publication number
JO3158B1
JO3158B1 JOP/2011/0125A JOP20110125A JO3158B1 JO 3158 B1 JO3158 B1 JO 3158B1 JO P20110125 A JOP20110125 A JO P20110125A JO 3158 B1 JO3158 B1 JO 3158B1
Authority
JO
Jordan
Prior art keywords
amino
fluorophenoxy
methylpyridine
carboxamide
monohydrate
Prior art date
Application number
JOP/2011/0125A
Other languages
English (en)
Inventor
Wichmann Saskia
Heilmann Werner
Gottfried Michael
Lögers Michael
Rehse Joachim
Stiehl Juergen
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44070712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3158(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Application granted granted Critical
Publication of JO3158B1 publication Critical patent/JO3158B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Containers And Plastic Fillers For Packaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

يتعلق الاختراع الحالي بعملية (process) لتحضير: 4-{4-[({[4-chloro-3-(trifluoromethyl)¬phenyl]amino}carbonyl)amino]-3-fluorophenoxy}-N-methylpyridine-2-carboxamide, أملاحه وmonohydrate منه.
JOP/2011/0125A 2010-04-15 2011-04-13 عملية تحضير 4- {4 - [({[4-كلورو-3- (ترايفلوروميثيل) -فينيل] أمينو} الكربونيل)أمينو]-3-فلوروفينوكسي}- } -n-ميثلبريدين-2-كربوكساميد، وملح ومونوهيدرات منه JO3158B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10004022 2010-04-15

Publications (1)

Publication Number Publication Date
JO3158B1 true JO3158B1 (ar) 2017-09-20

Family

ID=44070712

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2011/0125A JO3158B1 (ar) 2010-04-15 2011-04-13 عملية تحضير 4- {4 - [({[4-كلورو-3- (ترايفلوروميثيل) -فينيل] أمينو} الكربونيل)أمينو]-3-فلوروفينوكسي}- } -n-ميثلبريدين-2-كربوكساميد، وملح ومونوهيدرات منه

Country Status (39)

Country Link
US (5) US8748622B2 (ar)
EP (1) EP2558448B1 (ar)
JP (1) JP5934182B2 (ar)
KR (2) KR101800041B1 (ar)
CN (2) CN102947271B (ar)
AR (2) AR081060A1 (ar)
AU (1) AU2011240113B2 (ar)
BR (1) BR112012026117B1 (ar)
CA (1) CA2796238C (ar)
CL (1) CL2012002840A1 (ar)
CO (1) CO6630136A2 (ar)
CR (1) CR20120526A (ar)
CU (2) CU24123B1 (ar)
DK (1) DK2558448T3 (ar)
DO (2) DOP2012000268A (ar)
EC (1) ECSP12012234A (ar)
ES (1) ES2542610T3 (ar)
GT (1) GT201200280A (ar)
HK (1) HK1200831A1 (ar)
HR (1) HRP20150885T1 (ar)
HU (1) HUE026821T2 (ar)
IL (2) IL222348B (ar)
JO (1) JO3158B1 (ar)
MA (1) MA34156B1 (ar)
MX (1) MX2012011734A (ar)
MY (2) MY162359A (ar)
NZ (1) NZ602997A (ar)
PE (2) PE20160838A1 (ar)
PL (1) PL2558448T3 (ar)
PT (1) PT2558448E (ar)
RS (1) RS54219B1 (ar)
RU (1) RU2581585C2 (ar)
SG (2) SG10201501221UA (ar)
SI (1) SI2558448T1 (ar)
TN (1) TN2012000492A1 (ar)
TW (2) TWI475992B (ar)
UA (1) UA110613C2 (ar)
UY (2) UY33290A (ar)
WO (1) WO2011128261A1 (ar)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877933B2 (en) * 2004-09-29 2014-11-04 Bayer Intellectual Property Gmbh Thermodynamically stable form of a tosylate salt
CN101132779B (zh) 2005-03-07 2016-03-16 拜尔健康护理有限责任公司 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
UY35006A (es) 2012-09-06 2014-03-31 Bayer Healthcare Llc Composición farmacéutica recubierta que contiene regorafenib
SG11201501963RA (en) 2012-09-25 2015-04-29 Bayer Pharma AG Combination of regorafenib and acetylsalicylic acid for treating cancer
CN104250227A (zh) * 2013-06-29 2014-12-31 广东东阳光药业有限公司 瑞戈非尼新晶型及其制备方法
US9518020B2 (en) 2013-10-04 2016-12-13 Hetero Research Foundation Process for Regorafenib
CN105218439B (zh) * 2014-06-06 2018-11-20 连云港润众制药有限公司 一种瑞格非尼的晶体及其制备方法
WO2016005874A1 (en) * 2014-07-09 2016-01-14 Shilpa Medicare Limited Process for the preparation of regorafenib and its crystalline forms
CN104557689B (zh) * 2015-01-26 2016-06-29 重庆两江药物研发中心有限公司 制备4-[4-({[4-氯-3-(三氟甲基)苯基]氨基甲酰}氨基)-3-氟苯氧基]-n-甲基吡啶-2-甲酰胺及其一水合物的方法
CN104592105B (zh) * 2015-02-10 2017-01-18 杭州朱养心药业有限公司 瑞戈非尼及其制法
CN105330600B (zh) * 2015-11-30 2018-05-22 山东罗欣药业集团股份有限公司 一种瑞戈菲尼的制备方法
US20190300484A1 (en) * 2016-01-18 2019-10-03 Natco Pharma Ltd An improved process for the preparation of regorafenib
CN107118153A (zh) * 2016-02-25 2017-09-01 石药集团中奇制药技术（石家庄）有限公司 一种瑞戈非尼一水合物晶型及其制备方法
CN105879049B (zh) * 2016-05-13 2019-03-26 浙江大学 一种瑞戈非尼与β-环糊精的包合物及其制备方法
WO2018219807A1 (en) 2017-06-02 2018-12-06 Bayer Aktiengesellschaft Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
CN109438336B (zh) * 2018-11-27 2019-11-22 广东安诺药业股份有限公司 一种瑞戈非尼水合物的制备方法
CN109438337B (zh) * 2018-11-27 2019-08-09 广东安诺药业股份有限公司 一种瑞戈非尼中间体的制备工艺
EP3861989A1 (en) 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmaceutical composition containing regorafenib and a stabilizing agent
WO2021160708A1 (en) 2020-02-14 2021-08-19 Bayer Aktiengesellschaft Combination of regorafenib and msln-ttc for treating cancer
CN114315710B (zh) * 2022-01-07 2024-04-26 江苏豪森药业集团有限公司 一种制备或纯化瑞戈非尼的方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US20080269265A1 (en) 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
ME00275B (me) 1999-01-13 2011-02-10 Bayer Corp ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ES2384160T3 (es) 1999-01-13 2012-07-02 Bayer Healthcare Llc Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
ATE345130T1 (de) 2001-12-03 2006-12-15 Bayer Pharmaceuticals Corp Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
US10653684B2 (en) 2002-02-11 2020-05-19 Bayer Healthcare Llc Aryl ureas with angiogenisis inhibiting activity
CA2475818C (en) 2002-02-11 2011-07-19 Bayer Pharmaceuticals Corporation Aryl ureas as kinase inhibitors
EP1478358B1 (en) 2002-02-11 2013-07-03 Bayer HealthCare LLC Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
MXPA05012486A (es) 2003-05-20 2006-07-03 Bayer Pharmaceuticals Corp Diaril ureas para enfermedades mediadas por pdgfr.
US8637553B2 (en) 2003-07-23 2014-01-28 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
MXPA06012394A (es) 2004-04-30 2007-01-31 Bayer Pharmaceuticals Corp Derivados de pirazolilurea sustituidos utiles en el tratamiento de cancer.
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
ATE395905T1 (de) 2004-08-27 2008-06-15 Bayer Pharmaceuticals Corp Pharmazeutische zusammensetzungen in form fester dispersionen zur behandlung von krebs
US8877933B2 (en) 2004-09-29 2014-11-04 Bayer Intellectual Property Gmbh Thermodynamically stable form of a tosylate salt
US8124782B2 (en) 2004-09-29 2012-02-28 Bayer Pharma Aktiengesellschaft Process for the preparation of 4-{4-[({[4 chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide
CN101132779B (zh) 2005-03-07 2016-03-16 拜尔健康护理有限责任公司 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物
CA2627873A1 (en) 2005-10-31 2007-05-10 Scott Wilhelm Treatment of cancer with sorafenib
US20100144749A1 (en) 2005-11-14 2010-06-10 Scott Wilhelm Treatment of cancers with acquired resistance to kit inhibitors
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
JP2010509253A (ja) * 2006-11-09 2010-03-25 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト ４−［４−（｛［４−クロロ−３−（トリフルオロメチル）フェニル］カルバモイル｝アミノ）−３−フルオロフェノキシ］−ｎ−メチルピリジン−２−カルボキサミドの多形ｉｉｉ
CA2669158A1 (en) * 2006-11-14 2008-05-22 Bayer Schering Pharma Aktiengesellschaft Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
US8101773B2 (en) 2006-12-20 2012-01-24 Bayer Healthcare Llc Hydroxy methyl phenyl pyrazolyl urea compounds useful in the treatment of cancer
EP2114403A2 (en) 2007-01-19 2009-11-11 Bayer Healthcare, LLC Treatment of cancers having resistance to chemotherapeutic agents
US8680124B2 (en) 2007-01-19 2014-03-25 Bayer Healthcare Llc Treatment of cancers with acquired resistance to kit inhibitors
EP2156834A1 (en) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
CA2741087A1 (en) 2008-10-21 2010-04-29 Bayer Healthcare Llc Identification of signature genes associated with hepatocellular carcinoma
US20120059005A1 (en) 2009-05-15 2012-03-08 Novartis Ag Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) an antidiabetic compound for use in the treatment of proliferative diseases
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
EP2595628A1 (en) 2010-07-19 2013-05-29 Bayer HealthCare LLC Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
CA2813069A1 (en) 2010-10-01 2012-04-05 Bayer Intellectual Property Gmbh Substituted n-(2-arylamino)aryl sulfonamide-containing combinations
MX2013015287A (es) 2011-06-28 2014-03-31 Bayer Healthcare Llc Composicion farmaceutica oftalmologica topica que contiene regorafenib.
JP2014518232A (ja) 2011-06-28 2014-07-28 バイエル・ヘルスケア・エルエルシー ソラフェニブを含有する眼科用局所医薬組成物
US8841500B2 (en) 2011-11-08 2014-09-23 Chevron U.S.A. Inc. Preparation of alkyl aromatic compounds
JP2014032346A (ja) 2012-08-06 2014-02-20 Japan Display Inc 液晶表示パネル
UY35006A (es) 2012-09-06 2014-03-31 Bayer Healthcare Llc Composición farmacéutica recubierta que contiene regorafenib

Also Published As

Publication number Publication date
AR116395A2 (es) 2021-05-05
HRP20150885T1 (hr) 2015-10-09
PE20160838A1 (es) 2016-09-24
TN2012000492A1 (en) 2014-04-01
RU2581585C2 (ru) 2016-04-20
US20130116442A1 (en) 2013-05-09
WO2011128261A1 (en) 2011-10-20
EP2558448B1 (en) 2015-05-20
BR112012026117A2 (pt) 2015-09-08
SG184172A1 (en) 2012-11-29
IL222348A0 (en) 2012-12-31
KR20170129276A (ko) 2017-11-24
RU2012148386A (ru) 2014-05-20
CN102947271B (zh) 2016-11-09
UA110613C2 (uk) 2016-01-25
TWI475992B (zh) 2015-03-11
BR112012026117A8 (pt) 2017-12-19
DOP2016000285A (es) 2016-11-30
ECSP12012234A (es) 2012-11-30
CR20120526A (es) 2013-03-11
US20140221661A1 (en) 2014-08-07
CU24123B1 (es) 2015-08-27
MY162359A (en) 2017-06-15
AU2011240113A1 (en) 2012-10-11
AR081060A1 (es) 2012-06-06
SI2558448T1 (sl) 2015-11-30
NZ602997A (en) 2014-10-31
HK1200831A1 (en) 2015-08-14
CA2796238A1 (en) 2011-10-20
KR20130061670A (ko) 2013-06-11
CN103980191A (zh) 2014-08-13
CN102947271A (zh) 2013-02-27
US20190144391A1 (en) 2019-05-16
AU2011240113B2 (en) 2014-12-18
TW201204356A (en) 2012-02-01
CL2012002840A1 (es) 2013-01-18
TWI539951B (zh) 2016-07-01
MX2012011734A (es) 2012-12-17
UY33290A (es) 2011-12-01
BR112012026117B1 (pt) 2022-08-30
UY39590A (es) 2022-01-31
DOP2012000268A (es) 2012-12-15
MY177066A (en) 2020-09-03
IL253119A0 (en) 2017-08-31
US20170057918A1 (en) 2017-03-02
PL2558448T3 (pl) 2015-10-30
CA2796238C (en) 2019-12-31
CO6630136A2 (es) 2013-03-01
GT201200280A (es) 2014-07-23
MA34156B1 (fr) 2013-04-03
HUE026821T2 (en) 2016-07-28
IL253119B (en) 2018-03-29
US10822305B2 (en) 2020-11-03
RS54219B1 (en) 2015-12-31
CU20140060A7 (es) 2014-10-02
SG10201501221UA (en) 2015-04-29
US20170334857A1 (en) 2017-11-23
EP2558448A1 (en) 2013-02-20
CU20120147A7 (es) 2013-01-30
JP2013523851A (ja) 2013-06-17
US9458107B2 (en) 2016-10-04
JP5934182B2 (ja) 2016-06-15
US8748622B2 (en) 2014-06-10
DK2558448T3 (en) 2015-08-24
TW201509415A (zh) 2015-03-16
IL222348B (en) 2018-08-30
PE20130181A1 (es) 2013-02-23
ES2542610T3 (es) 2015-08-07
KR101800041B1 (ko) 2017-11-21
PT2558448E (pt) 2015-09-01

Similar Documents

Publication Publication Date Title
JO3158B1 (ar) عملية تحضير 4- {4 - [({[4-كلورو-3- (ترايفلوروميثيل) -فينيل] أمينو} الكربونيل)أمينو]-3-فلوروفينوكسي}- } -n-ميثلبريدين-2-كربوكساميد، وملح ومونوهيدرات منه
PH12015501328A1 (en) Meglumine salt of 6-flouro-3-hydroxy-2-pyrazine carboxamide
MY182428A (en) Crystalline forms of a prolyl hydroxylase inhibitor
MX2013006174A (es) Preparacion que comprende insulina, nicotinamida y un aminoacido.
MX337997B (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
UA110626C2 (uk) Спосіб одержання пан-інгібіторів циклінзалежної кінази формули (i), а також проміжні продукти цього процесу одержання
JO3189B1 (ar) طريقة جديدة لتخليق (e2) -3- (3, 4- داي ميثوكسي فينيل)بروب-2 - يننيتريل واستخدامها لتخليق ايفابرادين والاملاح المضافة منها مع حمض مقبول صيدلانيا
MY170662A (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
MY159691A (en) New process for the synthesis of 3-(2-bromo-4,5-dimethoxyphenyl)propanenitrile, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
SA113340924B1 (ar) عملية جديدة لتخليق 3- (2- برومو- 4،5 - داي ميثوكسي فينيل)بروبان نيتريل، وتطبيقها في تخليق إيڤابرادين وأملاح الإضافة منه مع حمض مقبول صيدلانياً
WO2011076711A3 (en) Polymorphs of salts of 4- [4- [ [4-chloro-3- (trifluoromethyl) phenyl] carbamoylamino] phenoxy] -n-methylpyridine - 2 - carboxamide
MX366887B (es) Tetrahidrato de la sal de l-arginina del ácido s-(-)-9-fluoro-6,7-dihidro-8- (4-hidroxipiperidin-1-il) -5-metil-1-oxo-1h, 5h-benzo[i,j] quinolizin-2-carboxílico puro, y un proceso para su preparación.
JO3083B1 (ar) عملية جديدة لتخليق إيفابرادين وأملاحه المضافة مع حمض مقبول صيدلانيا
TN2013000128A1 (en) Process for preparing pan-cdk inhibitors of the formula (1), and intermediates in the preparation